Investigating how TET inhibition can improve cancer immunotherapy
Exploring the potential of TET inhibition in cancer immunotherapy
This study is looking at a new way to boost cancer treatment by blocking certain enzymes that affect how our immune cells fight tumors, especially in tough-to-treat solid tumors, to help improve the success of CAR T cell therapy for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | La Jolla Institute for Immunology NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10977340 on NIH RePORTER |
What this research studies
This research explores a novel approach to enhance cancer immunotherapy by inhibiting TET enzymes, which play a role in modifying DNA to improve the immune response against tumors. The study focuses on how this inhibition can potentially increase the effectiveness of CAR T cells, particularly in treating solid tumors, which have been challenging to target effectively. By understanding the mechanisms of TET enzymes and their impact on T cell function, the research aims to develop strategies that could lead to better outcomes for patients with various types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with solid tumors or hematopoietic cancers like B-CLL who are seeking innovative treatment options.
Not a fit: Patients with non-cancerous conditions or those whose tumors are not solid or hematopoietic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments, particularly for patients with solid tumors who currently have limited options.
How similar studies have performed: While the approach of TET inhibition in cancer immunotherapy is relatively novel, previous studies have shown promise in enhancing immune responses through similar mechanisms.
Where this research is happening
La Jolla, United States
- La Jolla Institute for Immunology — La Jolla, United States (Active)
Researchers
- Principal investigator: Rao, Anjana — La Jolla Institute for Immunology
- Study coordinator: Rao, Anjana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.